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Platelet involvement in experimental immune complex-mediated gb-
merulonephritis in the nonhuman primate. Abundant glomerular platelet
deposition is a hallmark of certain animal models of immune complex
(IC)-mediated gbomerulonephritis (GN). By contrast, conspicuous
platelet deposition is uncommon in the IC-GN seen in humans. This
could result from intrinsic differences between human and animal
platelets, which are known to be present. To assess whether abundant
gbomerular platelet deposition can occur in humans with IC-GN, the
present studies were undertaken in nonhuman primates (cynomolgus
monkeys, CYN), with active experimental IC-GN induced by 12 weeks
of daily intravenous infusion of bovine gamma globulin (BOG). CYN
are appropriate for these studies because, like humans, CYN platelets
do not express the C3b receptor but do express receptors for the Fc
region of IgG (FcRyII). Furthermore, in this model of IC-ON, which is
indistinguishable from IC-GN seen in humans, it is possible to time the
biopsy to coincide with a period of peak activity of the GN. The present
studies proceeded as follows: ten CYN were studied before and after
intravenous infusion of BGG sufficient to achieve conditions near
antigen/antibody equivalence for circulating precipitating antibody to
BGG. The infusion of BGG, which was given over 10 minutes, resulted
in an acute reduction in circulating platelets (mean 43% 5 SE, P <
0.001). However, renal biopsies performed before and five minutes after
the acute reduction in circulating platelets showed that relatively few of
the platelets removed from the circulation lodged in glomeruli (platelets!
glomerular cross section: 0.2 0.06 before BGG vs. 0.88 0.31 after
BOG, P = 0.035). In five of the CYN studied under the above protocol,
autologous platelets were labeled with "In and reinfused into the CYN
just prior to the BGG infusion. These studies confirmed the paucity of
platelet deposition in kidney but showed major uptake of the 1'11n-
labeled platelets by liver and spleen (mean SE "In CPM/mg of tissue:
kidney cortex 18 8, liver 132 42, and spleen 808 127, P = 0.038,
comparing kidney to liver or spleen by paired t-test). Thus, the platelets
removed from the circulation were taken up at the sites which are also
the principal sites of IC uptake (liver and spleen), and over the time
interval that coincides with the period of maximum uptake of IC by liver
and spleen, after BGG infusion. In vitro studies, discussed herein,
showed that BGG anti-BGG IC bind to CYN platelets via FcRyII.
Thus, we suggest that, in vivo, circulating IC become bound to platelet
FcRyII and the platelet-IC complex is cleared from the circulation,
mainly by uptake by liver and spleen. Such a mechanism would divert
platelets, activated by ligation of IC, from sites of IC-mediated injury
such as the kidney. Such a mechanism would spare the kidney from
platelet-induced injury. In primates with an active experimental IC-GN,
which is comparable to GN seen in humans, platelets show little
tendency to lodge in gbomeruli. Instead, primate platelets appear to be
primarily involved in the clearance of IC from the circulation. These
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observations suggest that, with respect to the pathogenesis of IC-ON,
primate platelets may play a role that is different from that of rodent
platelets.
There are multiple lines of evidence suggesting that platelets
play an important role in the pathogenesis of glomerulonephritis
(GN). First, platelets contain procoagulant, chemotactic, and
mitogenic substances that, if released within the glomerulus,
could initiate or amplify the glomerulonephritic process [1, 21.
Second, platelet turnover is increased in humans with GN,
particularly in proliferative forms of GN [3—8]. Third, immun-
ofluorescent studies have identified certain platelet components
in the glomerulus in a wide variety of glomerulopathies in
humans [9—11]. Fourth, and by far the strongest evidence, are
the data from certain rodent models of GN showing that
glomerular platelet deposition is abundant and plays a critical
role in the pathogenesis of the GN [12—241.
Although the evidence is strong that platelets can play an
important role in rodent models of GN, the evidence is much
less clear in human GN. That is, unlike rodent models of GN in
which glomerular deposition of platelets is abundant, the search
for platelets in glomerular lesions in humans with GN has been
"disappointing" 111. Furthermore, the study which reported
localization of nuclide-labeled platelets to the kidneys of pa-
tients with GN could not be reproduced in subsequent studies
by the same investigators [25]. Finally, treatment of patients
with GN with drugs that inhibit platelet aggregation have
reduced the increased platelet turnover but have not been
effective in slowing the progression of the GN [reviewed in 81.
It has been suggested that the failure to find prominent
numbers of platelets in the glomeruli in humans with GN is
related to improper timing of the renal biopsy [1]. That is, in
animal models of GN, the biopsy can be performed at the time
of peak activity of the GN. However, determining when this
occurs in humans with GN is often not feasible. Furthermore,
studies in animals have shown that when platelets are deposited
in the glomerulus during the glomerulonephritic process, the
deposited platelets generally begin disappearing from the gb-
merulus within a few hours and may disappear entirely from the
glomerulus by 24 hours after the event that initiated platelet
deposition [17, 20]. Thus, if the renal biopsy is not properly
timed, platelet involvement in the glomerulonephritic process
could easily be missed.
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The observation of greater glomerular platelet deposition in
rodent IC-GN than humans with IC-GN might also be explained
if there is a stronger tendency for rodent platelets to lodge at
sites of tissue injury. This possibility is suggested by the fact
that rodent platelets express C3b receptors, but human platelets
do not [26]. Thus, the C3b that is abundantly deposited at sites
of immune injury [271 could mediate the localization of rodent
platelets to those sites. Indeed, if rodents are depleted of C3
prior to induction of the glomerulonephritic process, platelets
do not localize to the glomerulus and glomerular injury is
greatly reduced [17, 19—21, 23]. Thus, the C3b receptors on
rodent platelets could account, at least in part, for the abundant
glomerular platelet accumulation seen in rodent models of GN.
Although primate platelets do not express C3b receptors,
primate platelets do express FcR7II, and receptors for the C3
breakdown products C3bi, C3dg, and C3d [28]. Thus, these
receptors might mediate binding of platelets to sites of IC
deposition and IC-mediated injury.
The present study was undertaken to assess the potential for
primate platelets to localize to sites of glomerular immune
injury, and to assess how circulating platelets are affected in
vivo in the primate when large amounts of IC form in the
circulation.
Methods
Ten cynomolgus monkeys (CYN) were studied, nine males
and one female. All CYN were purchased from the Charles
River Primate Center (Houston, Texas, USA). Prior to entering
our primate colony they were observed for four weeks in
quarantine and were found to be normal on physical examina-
tion, have normal serum chemistries, complete blood count,
urinalysis, and to be free of tuberculosis. The diet consisted of
monkey chow, fresh fruit and water ad libitum. The CYN were
evaluated every one to two weeks by a veterinarian and were
weighed weekly during study periods.
The CYN involved in the present study completed participa-
tion in a study examining the effect of enalapril therapy versus
placebo on the progression of a model of experimental IC-GN
induced by daily (Monday through Friday) infusion of BGG [29,
30]. At the time of the present study, the CYN had received a
total of 12 weeks of daily intravenous infusion of BGG, the last
four weeks of which the CYN received either enalapril or
placebo. All CYN had established GN as shown by abnormal
proteinuria and renal biopsy demonstrating abundant glomeru-
lar IC deposition. Each enalapriuiplacebo study concluded on a
Friday morning at which time each CYN received an infusion of
BGG and its last dose of enalapril or placebo [29]. The present
study, which was a terminal protocol, took place on the next
Tuesday. Thus, the CYN involved in this study had not
received enalapril or BGG for four days. This four day interval
is mentioned because when BGG is infused daily (Monday
through Friday) in amounts approximating antigen/antibody
equivalence for circulating precipitating antibody to BGG, there
is a progressive fall during the week in BGG antibody levels and
in circulating platelet counts [30]. The nadir for BGG antibody
levels and platelet counts is seen by Friday. However, when no
BGG is given on Saturday and Sunday, by Monday, BGG
antibody titers and platelet counts have increased to baseline
levels [30]. The "rebound" in BGG antibody and platelet levels
over the weekend is, apparently, the result of not administering
the BGG on Saturday and Sunday. Thus, at the time of the
present study, the platelet counts had returned to normal and
BGG antibody levels were at peak levels. Also, because the
CYN in the present study had normal GFR (as assessed by
normal serum creatinine levels) and this present study was
performed four days after the last dose of enalapril, it is likely
that little or no enalapril was present in the circulation at the
time of the present study.
Study protocol
Each CYN received ketamine 6 mg/kg intramuscularly as a
pre-anesthetic. The CYN were then intubated and general
anesthesia was maintained with halothane, as previously de-
scribed [30]. A midline abdominal incision was performed so
that a biopsy of the splanchnic organs could be accomplished.
Blood pressure was monitored using an automatic blood pres-
sure measuring device with a pediatric blood pressure cuff.
Each study commenced with a baseline renal biopsy and
measurement of the blood platelet count. The renal biopsy
consisted of a wedge of cortex taken from an area of cortex
which had not previously been a site of a needle biopsy (each
CYN had previously undergone 3 or 4 closed needle biopsies of
the kidney). Each CYN was then infused over 10 minutes with
a dose of BGG which was calculated to achieve conditions
approximating antigen-antibody equivalence for the circulating
precipitating antibody to BGG [30]. This dose is the same as
that used Wednesday through Friday during the 12 weeks of
GN induction [301. Five minutes after completion of the BGG
infusion (15 minutes after the start of the BGG infusion), the
open renal biopsy was repeated, taking a wedge of cortex from
a site in the contralateral kidney which had not previously been
the site of a needle biopsy. The CYN was then sacrificed.
Platelet localization studies
In five of the CYN studied under the above protocol, the fate
of autologous "In-labeled platelets was studied simultaneously
with the execution of the above protocol as follows: the
platelets were labeled by methods previously reported [31—33].
Briefly, 8.5 ml of whole blood were drawn into 1.6 ml of
acid-citrate-dextrose (ACD) solution and centriluged at 200 x g
for 12 minutes. The platelet-rich plasma was recovered and
centrifuged at 640 x g for 10 minutes. The plasma was removed
and the platelets were rinsed once with one ml of ACD, 0.15 M
saline (ACD-S), and then gently resuspended in 0.8 ml of
ACD-S. One hundred Ci of "In was added and the platelet
suspension was incubated at 37°C for one minute. One ml of
plasma, diluted '/2 with ACD-S, was added, and the platelets
were further incubated at 37°C for five minutes. The labeled
platelets were pelleted at 650 x g for 10 minutes, and then
gently resuspended in 1 ml of plasma containing 0.4% trisodium
citrate.
The platelets were then re-infused into the CYN over 15
minutes and allowed to equilibrate for 15 minutes. The CYN
then received the BGG infusion over 10 minutes. Five minutes
later (15 minutes after the start of the BGG infusion) the CYN
was sacrificed and ito 3 g samples of kidney cortex, liver, lung,
and spleen were obtained to determine "In CPM/mg of tissue.
Blood samples were obtained before and 15 minutes after the
start of the BGG infusion to determine the amount of "In CPM
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associated with packed blood cells (containing the labeled
platelets) and with plasma, from 1 ml of whole blood.
In vitro studies to assess the mechanism of binding of BGG/
anti-BGG immune complexes to CYN platelets
Platelets were isolated from normal cynomolgus blood sam-
ples using differential centrifugation as outlined above, and
resuspended in 1 ml of 0.01 M phosphate, 0.15 M NaC1, pH 7.4
(PBS). Precipitable IC were prepared by incubating 2 s1 of 125j
labeled BGG (12 g) with 50 sl of CYN anti-BGG EDTA
plasma and 1 ml of PBS at 37°C for 30 minutes, and then
overnight at 4°C. After washing and resuspension of the IC
precipitates in 200 td PBS, 25 sl of IC were mixed with 6.25 d
serum from the same CYN and either 7.5 JLl PBS for formation
of IC with complement (IC-C) or with 7.5 .d PBS with 0.08 M
EDTA for formation of IC without complement (IC-E). The
samples were incubated at 37°C for five minutes, washed with
PBS, 0.015 M EDTA, and then resuspended in 100 pi PBS. The
binding studies involved incubating 25 j.d of platelets with 20 s1
of IC-C or IC-E in the presence of varying amounts of purified
mouse monoclonal anti-FcRyII antibody (1V3, a gift of Dr.
Clark Anderson) or MOPC 141 IgG2b control at 37°C for 10
minutes. The reaction mixtures were then placed over 30%
isotonic percoll and centrifuged at 500 x g for five minutes. The
supernatants were aspirated, and the pellets and supernatants
were measured for 125j radioactivity.
Routine and quantitative electron microscopy
Routine EM was performed on small samples of the biopsy
material that contained glomeruli that were immersion fixed for
4 to 12 hours in 1% glutaraldehyde in Millonigs phosphate buffer
pH 7.4. After osmic acid post-fixation, dehydration and embed-
ding in Polybed, one-micron sections were obtained. Large
glomeruli at least one tubule width in from the edge of the
section were selected and 50 nm thin sections obtained. Brief
lead citrate and uranyl acetate staining was used. All renal
biopsy specimens were coded and read without knowledge of
group assignment of the CYN. Glomerular histomorphometry
was performed by use of a Gatan video monitor attached to the
Hitachi 600 standard transmission electron microscope, as
previously described [30]. Four histomorphometric studies
were performed per biopsy sample on 4 glomeruli sectioned at
their fullest width.
Glomerular components. Standard point counting techniques
were used, as previously described [30]. In brief, a transparent
grid containing 40 equally spaced points was attached to the
video screen. Randomly selected areas of the glomerulus were
imaged at 53,000 magnification to provide at least 800 points per
glomerulus and the fractional volume of the glomerular mesan-
gial cell, mesangial matrix, and GBM was calculated for each
animal.
GBM deposits. Random GBM regions encountered during
the glomerular component determination were viewed at 41,000
magnification and the GBM length measured on the video
monitor, The length of lamina rara interna, lamina densa, and
lamina rara externa electron dense deposits was also directly
measured on the screen and the percent of LRI, LD, and LRE
involved with electron dense deposits was calculated.
Mesangial deposits. Random mesangial matrix areas encoun-
tered during the glomerular component determination were
viewed at 41,000 magnification. The number of points of the
40-point transparency grid that fell on mesangial electron dense
deposits and the number of points that fell on mesangial matrix
were determined. The percent of mesangial matrix with depos-
its was then calculated for each glomerulus and averaged for
each biopsy.
Leukocytes and platelets per glomerulus. The total number of
leukocytes and platelets that were encountered during scanning
of the entire glomerular cross section available for the glomer-
ular component determination were identified for each glomer-
ulus. The average number of leukocytes and platelets per
glomerulus was then calculated from the values obtained from
the four glomeruli examined per biopsy.
Analytical techniques
Precipitating antibody levels to BGG were determined as
previously described [30]. The equivalence point was taken as
the inflection point in the quantitative precipitin curve [30].
Erythrocyte complement receptor Type 1 (CR1) levels were
determined by quantitating the binding of '251-El 1 antibody, as
previously described [30]. All other assays were performed
using standard techniques in the clinical laboratories of The
Ohio State University Hospitals.
Statistical methods
All mean values are shown standard error of the mean
(5EM). The statistical tests used to analyze the data are dis-
cussed in relationship to the data.
Results
Clinical characteristics of the CYN at the time of the present
study
As can be seen from Table 1, at the time of this study, most
CYN had abnormal proteinuria. The normal urine protein/urine
creatinine ratio, both protein and creatinine concentrations
expressed in mg/dl, is 0.18 0.13 SD, median 0.13, (N = 25
CYN). However, the serum creatinine levels were within the
normal range and not increased from serum creatinine levels
measured prior to the start of the GN-Induction Protocol (data
not shown). All CYN had high levels of precipitating antibody
to BGG [30]. The dose of BGG shown in Table 1 was that given
in the present study.
Effect of BGG infusion on glomerular morphometry and
accumulation of platelets and leukocytes
Figure 1 shows a representative photomicrograph of a renal
biopsy from one of the CYN involved in this study. The biopsy
was obtained 15 minutes after infusion of BGG, at a time when
approximately 40% of the circulating platelets had acutely
disappeared from the circulation. As can be seen, no platelets
are observed but there are abundant electron dense deposits in
mesangium and in relation to the glomerular capillary wall.
Table 2 shows the morphometric analysis of glomerular
mesangium and immune deposits, and enumeration of leuko-
cytes and platelets per glomerular cross section, for all of the
CYN involved in this study. The morphometric measurements
were made before and 15 minutes after the start of BGG
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Table 1. Clinical characteristics of the CYN at the time of the present study
CYN Weighta Sexb aBGGC BGGd Scre Plt'
La 4.4 M 186 45.1 0.7 5.8 680 0.7
Ma 6.1 M 189 62.5 0.7 0.11 925 1.6
No 5.2 M 182 53.2 0.8 2.8 690 3.7
01 4.9 M 183 50.2 0.9 2.0 510 2.3
Pa 5.0 M 185 51.2 0.4 0.35 570 1.2
Du 3.8 M 100 38.9 0.8 0.26 810 2.6
Ir 4.2 F 82 21.5 1.3 0.88 590 5.1
Le 4.9 M 161 50.2 0.5 1.80 200 3.1
To 6.4 M 3.2 16.2 0,7 0.18 245 4.1
Wi 5.0 M 13.4 12.8 0.7 2.7 285 3.1
X SE 5.0 0.2 128 23 40.2 5.5 0.75 0.1 1.7 0.6 550 80 2.7 0.4
a Kilograms
b Male (M), female (F)
g BGG precipitated/mI of serum at equivalence
dose, mg
Serum creatinine, mg/dl
(Urine protein, mg/dl)/(Urine creatinine, mg/dl)
g Average number of complement receptor type 1 on erythrocytes
h Platelets/mm3 of blood x
infusion. Renal biopsies done 16 weeks earlier (before immuni-
zation to BGG) showed normal glomerular morphometry. Thus,
the glomerular electron dense deposits enumerated in Table 1
represent the deposits which accumulated during the previous
12 weeks of daily BGG infusion. These deposits represent IC as
shown by the fact that the deposits stain with antibodies to
immunoglobulins (IgG) and C3, as described previously [30].
Table 2 shows that a single dose of BUG causes no significant
change in the amount or location of the electron dense deposits.
However, the BGG infusion did result in a small but significant
increase in the numbers of leukocyte and platelets per glomer-
ular cross section, and a significant acute increase in mesangial
volume.
Effect of BGG infusion on circulating platelets
Table 3 shows the changes in daily platelet counts that were
observed in five of the CYN involved in the present study,
during the week prior to the present study. The changes in
platelet counts shown in Table 3 are typical of those previously
reported in CYN receiving similar intravenous daily doses of
BOG during a GN-Induction Protocol [30]. That is, platelet
counts decrease progressively with each day of BOG infusion,
as reflected by Thursday values. However, on the days when
BOG is not infused (Saturday and Sunday) platelet counts
increase to their normal levels, as reflected by Monday (pre-
BOG infusion) levels.
Figure 2 shows the changes in circulating platelets following
BOG infusion on the day of the present study in the five CYN
involved in the platelet localization studies (described below).
As can be seen, the percent change in 'DIn CPM/ml of blood
correlates well with the percent change in directly measured
platelet counts, indicating that the 'In in blood reflects the fate
of platelets in the circulation.
Figure 3 shows the amount of "In radioactivity associated
with the packed cells (labeled platelets) and in the plasma
(evidence of platelet lysis) from 1 ml of whole blood drawn
before and 15 minutes after start of the BGG infusion. As can be
seen, in one of the five CYN, there is a sharp increase in the
radioactivity found in the plasma. Presumably this reflects lysis
of platelets with release of the "In-labeled intracellular pro-
teins [31] into the plasma.
Tissue localization of platelets following infusion of BGG
The five CYN described in the above experiments were
sacrificed 15 minutes after the start of the 10 minutes BUG
infusion, and tissue samples were obtained from the splanchnic
organs to assess localization of platelets. The timepoint, 15
minutes from the start of the BGG infusion, was chosen
because the platelet count reaches its nadir [30], and the
clearance of IC from the circulation is nearly complete [34] by
this time. As shown in Table 4, the great majority of the
"In-labeled platelets removed from the circulation was taken
up by liver and spleen. Relatively few of the "In-labeled
platelets are found in kidney. Although liver did not have the
highest "In CPM/mg, in primates the average liver is 10 times
larger than the average spleen or lung [28]. Thus liver is the
major site of platelet uptake. Liver is also the major site of IC
uptake [28]. The data in Table 4 also confirm the morphometric
studies showing that very few of the platelets removed from the
circulation during IC clearance lodge in the glomerulus.
In vitro studies assessing the mechanism of binding of
immune complexes to cynomolgus platelets
In vitro studies were undertaken to assess if the IC that were
used in this study bound to CYN platelets and, if so, which
platelet receptor mediated this binding. Freshly isolated CYN
platelets were incubated with IC, with (IC-C) or without (IC-E)
deposited complement components, and in the presence of blOck-
ing anti-FcyRII antibody (1V3) or an irrelevant antibody (MOPC
141). The results of these experiments for the three CYN studied
are shown in Table 5. As can be seen, IC-E bound to CYN
platelets. This binding was reduced in a dose dependent manner
by 1V3, the anti-FcyRJI antibody, while the class-specific control
antibody (MOPC 141) had no effect on IC binding. IC-C also
bound to CYN platelets. 1V3 reduced the binding of IC-C to
platelets to the same level as it reduced the binding of IC-E to
platelets, indicating that complement does not mediate the
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Fig. 1. Representative electron
photomicrograph of a renal biopsy specimen
from CYN LA taken 5 minutes after
completion of BGG infusion. At 3000x
electron dense deposits are seen in the para
mesangium (triangular arrowhead) and in
relation to the glomerular capillary wall
(arrowhead). No platelets are seen. At
l4,000x (inset) glomerular capillary wall
deposits are seen in more detail. An
arrowhead indicates a large subepithelial
deposit.
binding of IC to CYN platelets. In fact, CYN platelets bound
IC-C to a lesser extent than IC-E, suggesting that the binding of
IC to CYN platelets is reduced by the deposition of complement
on the IC. This observation could be explained by deposited
C3b sterically hindering the interaction of Fc and platelet
FcyRII. It is also possible that smaller immune complexes form
in the presence of complement activation and these smaller IC
bind less well to platelets [271.
To assess whether 1251-BGG itself can bind to CYN platelets,
a separate experiment was carried out, in which the binding of
'251-BGG to CYN platelets was assessed. The methods used
were the same as those described above. The study showed that
the percent binding of '251-BGG to CYN platelets was 4.6 0.5.
When the '251-BGG IC were formed by the addition of immune
CYN serum, the percent binding of the '251-BGG IC to the same
CYN platelets was 75.9 0.9. Thus, the present studies
indicate that the binding of '251-BGG to CYN is specifically the
result of IC formation with '251-BGG, and that the IC bind to
platelets via Fc7RII interactions, but not by complement-
mediated mechanisms.
Discussion
The present study shows that intravenous infusion of BGG
into CYN that have high precipitating antibody levels to BGG
results in an acute reduction in circulating platelets. The acute
reduction in circulating platelets is probably the result of the
formation in the circulation of IC that bind to platelet FcR'yII
receptors. The platelets with IC bound to them are then
removed from the circulation primarily by liver and spleen. This
interpretation is based on: (1) the present in vitro studies
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Table 2. Morphometric analysis of the renal biopsies taken before (pre) and 5 minutes after (post) BGG infusion in 10 CYN with
active IC-GN
WBC/
CYN Mesvola LREb LDC LRId Mesdepe glom PL/g1om
LA
pre 21.4 1.6 0.0 17.2 26.5 2.3 0.3
post 31.3 0.2 2.8 18.3 25.1 3.6 1.3
MA
pre 18.8 1.6 0.0 1.0 8.6 0.6 0.0
post 28.3 0.0 0.9 0.0 15.8 1.0 0.3
NO
pre 29.7 1.1 0.6 2.7 9.0 0.3 0.0
post 47.7 0.0 1.1 4.9 16.3 1.0 0.0
OL
pre 23.0 0.0 0.0 0.0 13.1 1.6 0.3
post 28.8 0.4 0.4 0.2 6.1 2.6 1.3
PA
pre 20.0 0.0 0.0 0.0 8.5 0.3 0.3
post 19.5 0.4 1.1 0.2 12.5 1.0 0.3
DU
pre 28.2 0 0 0 4.8 1.0 0.0
post 24.3 0.5 0.2 0 4.7 0.3 0.3
IR
pre 21.3 8.8 7.4 20.9 16.6 3.6 0.6
post 20.8 7.5 4.7 21.8 21.7 5.3 3.0
LE
pre 23.4 2.1 1.7 17.0 26.7 0.6 0.0
post 27.8 3.5 2.5 13.5 27.0 1.3 0.3
TO
pre 16.7 1.4 0.4 0 27.7 1.6 0.3
post 22.6 0.6 0.6 0 21.5 2.0 0.0
WI
pre 21.0 1.7 0.1 0.1 4.2 1.3 0.3
post 22.0 2.0 0 0.1 5.1 2.0 2.0
X x SE
pre 22.4 1.2 1.8 0.8 1.0 0.7 5.8 2.8 14.6 2.9 1.3 0.3 0.21 0.06
post 27.3 2.6 1.5 0.8 1.4 0.5 5.9 2.7 15.6 2.6 2.0 0.5 0.88 0.3
P value1' 0.037 NS NS NS NS 0.007 0.035
a Relative mesangial volume (matrix + cells)
b Lamina rara electron dense deposits
C Lamina densa electron dense depositsd Lamina rara interna electron dense deposits (the GBM deposits are expressed as the percent of GBM length occupied by deposit)
Mesangial electron dense deposits expressed as a percent of mesangial volume occupied by deposit
Neutrophils/glomerular cross section
g Platelets per glomerular cross section (150 m diameter)h Paired t-test
showing that IC bind to CYN platelets through the FcRyII
receptors expressed on CYN platelets, and (2) the present in
vivo studies showing localization of platelets mainly to liver and
spleen over the same time period in which previous studies in
nonhuman primates have shown localization of IC to liver and
spleen [29].
The fact that large numbers of platelets are removed from the
circulation during IC clearance might lead to the expectation
that many of the platelets will become lodged within the
glomerulus. However, renal biopsies performed within minutes
of completing the infusion of BGG, and at a time that cone-
sponds to the nadir of circulating platelets, demonstrated that
relatively few of the platelets lodged in glomeruli. The morpho-
metric assessment of a paucity of platelet deposition in glomer-
uli was confirmed by the studies using 'In-labeled platelets
which showed little In in kidney cortex.
It is unlikely that platelets lodged within the glomerulus and
then were released back into the circulation before the renal
biopsies were taken because previous studies have shown that
Table 3. Platelet counts measured near the end of a week of daily
BGG infusion (Thursday), after two days of no BGG infusion
(Monday, "pre"), 5 minutes after BGG infusion (Monday, "post"),
and 24 hours after the Monday infusion of BGG (Tuesday)
CYN





Du 1.4 4.5 1.5 2.5
Le 2.2 3.7 2.6 3.4
Wi 4.6 5.9 5.0 5.2
Ir 3.6 7.7 7.4 5.6
To 6.8 9.4 7.6 8.5
X X SE 3.7 0.9 6.2 1.0 4.8 12b 5.0 1.0
a P = 0.008, compared to Monday "pre" values by paired t-testb p = 0.037, compared to Monday "pre" values by paired t-test
when platelets lodge in the glomeruli during the glomerulone-
phritic process, the platelets are identifiable in glomeruli for at
least a few hours [17, 20]. Thus, it seems most likely that, in the











% Change in platelets/mm3
Fig. 2. Relationship between the percent change in platelets/mm3 of
blood, and percent change in "In CPM/ml of blood (labeled platelets),
which occurred during the infusion of BGG in CYN infused previously
with autologous platelets labeled with "In. The correlation coefficient
of this relationship is r = 0.997, P < 0.001. The results of the individual
CYN can be identified as follows: WI (closed circle), LE (cross), TO
(closed square), DU (diamond), IR (triangle).
present study, platelets did not lodge within glomeruli in large
numbers.
It can be calculated that if only 1% of the platelets removed
from the circulation (assuming a platelet reduction of 100,000/
mm3 of blood) had lodged in the glomeruli (assuming 100,000
glomeruli per CYN (35, 36]), a greater than 40-fold increase
[from 0.21 PL/glom (Table 2) to 10 PL/glom] in the number of
platelets per cross section should have been identified. How-
ever, an increase of less than 1 platelet per glomerular cross
section was noted in the present studies. This is further evi-
dence that in primates there is little tendency for platelets to
lodge in glomeruli under conditions of active IC-GN.
The present study shows that circulating leukocytes, which
are also acutely reduced in number during infusion of BGG [301
lodge in the glomeruli but only in small numbers, relative to the
numbers of leukocytes removed from the circulation [301.
Our studies, which demonstrate minimal involvement of
platelets in the glomerulonephntic process, appear to be at odds
with a large number of studies of experimental GN in other
animals species, particularly rodents. Those studies show that
large numbers of platelets become trapped in glomeruli when IC
form within the kidney by infusion of antibodies that bind either
to "planted" antigens [14, 16] or to endogenous antigens [12,
18, 201, or when immune complexes are infused into the renal
artery, or IC are formed by infusing antigen into the circulation
of rodents that have been actively or passively immunized to
that antigen [37—44]. In addition, if platelet accumulation in the
glomerulus is prevented by depleting the rodent of platelets, or
by complement depleting the rodent, generally the nephritic
process is greatly ameliorated [12, 16, 17, 19—21, 23, 241. This
indicates that platelets play a critical role in the pathogenesis of
IC-ON in these rodent models.
The difference between our present observations in the
primate, which demonstrate little deposition of platelets during
the glomerulonephritic process, and previous studies in the
rodent, which often demonstrated extensive deposition of plate-
lets during the glomerulonephritic process, could be explained
by differences between primate and rodent platelets. Key
differences are as follows:
(1.) The platelets of rodents express abundant C3b receptors
[28]. Platelet C3b receptors could account for the lodging of
platelets at sites of complement-mediated injury in which the
C3b deposited at those sites binds to the C3b receptors on
circulating platelets.
(2.) The vasoactive amine content of rabbit platelets is ap-
proximately 20 to 30 times greater than that of primate platelets
[1, 2]. This could be relevant to the process of IC trapping
because local release of vasoactive amines may favor the local
uptake of circulating antigen, antibodies or IC [1, 2]. Thus,
increased release of vasoactive amines from rodent platelets
could increase IC deposition and secondarily increase platelet
deposition at sites of IC deposition.
(3.) Primate platelets express Fc receptors (FcRyII) [45].
The Fc receptor system on primate platelets might be important
in diverting activated platelets to liver and spleen. That is, when
platelets with high Fc receptor densities and/or affinities (those
platelets most likely to bind to circulating IC) bind to IC in the
circulation and become activated [46, 47], those platelets may
be preferentially removed from the circulation and deposited in
liver and spleen, as suggested by the present observations.
Thus, unlike rodent platelets, which may preferentially localize
to sites of injury in which C3b is heavily deposited, primate
platelets may be diverted away from sites of IC injury by
interaction with circulating IC.
It is also possible that the differences in glomeriilar platelet
deposition between primates and rodents with GN are related to
differences in the severity of the glomerulonephritis. That is, in
many (but not all) of the studies in rodents, the conditions
which led to the ON represented experimental conditions more
severe than those of the present study. For example, in the
rodent studies, typically a large amount of IC or antigen was
infused directly into the renal artery (41—44], or large amounts
of antigen were planted in the glomerulus, followed by direct
infusion of large amounts of antibody into the renal artery [14,
16, 171. Indeed, it is possible that such experimental conditions,
which demonstrate abundant glomerular platelet deposition, are
so severe that they cannot occur naturally.
Although severe experimental conditions may explain some
of the reported differences in the glomerular localization of
platelets in the GN of rodents compared to that of human and
nonhuman primates, severe conditions do not seem to explain
all of the observed differences. That is, there have been several
reports of abundant platelet deposition occurring in the glomer-
uli of rodents in which the model of experimental ON appeared
to be entirely comparable (daily intravenous infusion of antigen)
to that of the present study [37—40, 42, 43]. By contrast, in our
previous studies involving more than 100 renal biopsies in more
than 30 CYN with experimental IC-ON, we have never ob-
served more than an occasional platelet within glomerular
capillaries [30, unpublished observations].
It is possible that platelets were involved in the glomerislo-
nephritic process in the present study, but only indirectly. For
example, lysis of platelets in the circulation (see Results) could
have resulted in the glomerular trapping of proteins released
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Fig. 3. A. '111n CPM in packed cells/mi of blood (labeled platelets)
beforeand 15 minutes after the start of the BGG infusion. B. "'In CPM
in plasma/mi of blood, before and 15 minutes after the start of the BGG
infusion. In one of the CYN shown in B, there is a sharp increase in
"In CPM in plasma indicating that lysis of platelets has occurred. The
conventions for Figure 3 are the same as those for Figure 2.
Table 4. Tissue localization of platelets 5 minutes after BGG
infusion, as assessed by tissue uptake of 1111n-labeled platelets
CPM/mg of tissuea
Kidney
CYN (Cortex) Spleen Liver Lung
Du 12 802 146 224
Ir 23 588 100 43
Le 2 1280 286 138
To 4 786 36 30
Wi 47 586 92 31
X±sE 188b 808±127 132±42 93±38
a The CPM/mg of tissue were corrected for "In contained in
vascular volume [28]
b p < 0.01 comparing kidney cortex to spleen or liver by paired t-test
Table 5. The binding of IC to the platelets of three CYN (Qu, Ir, Or)
in vitro
IC mAbb g/mF
% IC bound to platelets
Qu Ir Or
ICEa — 89 83 77
IC-E 1V3 250 — 22 12
IC-E 1V3 25 17 18
IC-E 1V3 1 48 54
IC-E 1V3 .04 89
IC-E 141 250 78 76
IC-E 141 25 88
ICCd — 29 57 59
IC-C 1V3 250 19 3
IC-C 1V3 25 17
IC-C 141 250 65
IC-C 141 25 31
a Immune complexes formed in the presence
autologous serum (No C3b deposited on IC)
b Monoclonal antibody added to platelet suspension prior to addition
of IC
Final concentration of monoclonal antibody
ci Immune complexes formed in fresh autologous serum (C3b depos-
ited on IC)
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into the general circulation from the platelets undergoing lysis.
However, if glomerular trapping of platelet proteins had oc-
curred to a large extent this might have been revealed in our
studies by high "In in renal cortex, because "In labels
intracellular platelet proteins [31, 33]. However, relatively little
WIn was found in renal cortex in the present study. This
suggests that glomerular uptake of platelet intracellular proteins
is not a prominent feature of this model of IC-GN. Neverthe-
less, such a process could account for small amounts of
CPM in renal cortex in the present study, and for the platelet-
derived proteins observed in glomeruli by immunofluorescence
studies in previous studies of GN in humans [9—111.
The model of IC-GN in our nonhuman primates is indistin-
guishable from forms of IC-GN seen clinically. For example,
the glomerulonephritis of SLE or IgA nephritis in humans in
many instances would be indistinguishable from the histologies
we observe in this model of IC-Gn in the CYN.
In summary, the present studies suggest that in primates,
platelets interact with IC that form in the circulation resulting in
the uptake of large numbers of platelets and IC by liver and
spleen. During this process, relatively few platelets lodge in
glomeruli. These observations suggest that when IC form in the
circulation of primates, the platelets that bind to IC are diverted
primarily to liver and spleen, and away from sites of IC injury
in the glomerulus. These observations can explain the finding in
humans with GN that platelet turnover is increased [3—8] but
renal biopsies show inconspicuous numbers of platelets in
glomeruli [1].
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